Inovio Pharmaceuticals Inc vs Procter & Gamble Co — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $76.09M), while Procter & Gamble Co trades at $145.12 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 4473.5× Inovio Pharmaceuticals Inc's market cap, and Procter & Gamble Co pays a 2.97% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PG | |
|---|---|---|
Market Cap | $76.09M | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $167.18 |
52-Week Low | $0.66 | $138.10 |
Enterprise Value | $47.10M | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.
High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.
Procter & Gamble (PG) trades at $146.38, up 0.42% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.90. Revenue reached $84.28B in 2025, with a net income margin of 18.44% and robust cash flow from operations of $17.82B. Analyst consensus is bullish with a $161.20 price target, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.
The outlook for PG is positive due to steady earnings growth and dividend reliability, but risks include premium valuation concerns and soft demand headwinds. Investors may find opportunity in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →